Please sign in to follow a disease.
Curcumin and fish oil tested to shrink Smokers' lung nodules
NCT ID NCT03598309
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests whether a combination of curcumin (from turmeric) and fish oil can reduce the size of lung nodules in former and current smokers aged 55 and older. Nineteen participants took the supplements or a placebo for 6 months. The study aims to see if the nodules shrink and if the treatment is safe.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Curcumin C3 Complex and Omega-3-Acid Ethyl Esters (fish oil)
- What this could lead to
- If it works, this could point toward a way to reduce lung nodules in smokers, potentially lowering cancer risk.
- What could go wrong
- This is a very small, early-phase trial with only 19 participants. The results may not apply to everyone, and the supplements might not shrink nodules or could cause side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2
Tests whether the treatment actually works, and watches for side effects, in a larger group.
- Participants
-
19 people
The number who actually took part.
- Started
-
Jun 2019
- Expected to finish
-
May 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
55 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Male or female, 55 years of age or older * Former smokers and current enrolled in LDCT lung cancer screening or those who are detected using a regular CT, and have Lung-RADS 3 category lesion(s), that would get a 6 month f/u LDCT or regular CT based on Lung-RADS recommendations or former and current smokers enrolled in LDCT lung cancer screening, or regular CT and have Lung-RADS 2 category lesions with part-solid or non-solid lung nodule ≥4mm mean diameter detected during screening LDCT or regular CT scans * History of cigarette smoking with ≥ 20 pack years * All current smokers should accept to receive smoking cessation * Eastern Cooperative Oncology Group (ECOG) Performance Status of less than or equal to 1 * Able to swallow study pills * Able to undergo CT * Not allergic to components of study agents * Willing to discontinue current vitamin/mineral supplement use containing components of study agents. A standard multivitamin supplement provided for the study * Willing to comply with proposed visit and treatment schedule * Able to understand and willing to sign a written informed consent document * Participants must have normal organ and marrow function * Willing to use contraception during the intervention period of 6 months (males and females) * Not pregnant or lactating nor planning to become pregnant or lactate during the 6 month study intervention period.. Exclusion Criteria: * Invasive cancer diagnosis (excluding basal cell carcinoma or skin squamous cell carcinoma) diagnosed within the last 2 years * Inability to undergo CT * Newly diagnosed nodule meeting Lung-RADS 4 criteria * Have taken doxycycline or tetracycline less than or equal to 2 weeks * Females- pregnant or lactating (throughout the duration of intervention of 6 months) * Unwilling to use effective form of birth control (Males and females) (throughout the duration of intervention of 6 months).
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Lung cancer, protection against are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, 33612, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Breathing tube before sedation: a safer path for complex lung scopes?
- Which nerve block wins for lung surgery pain?
- Could a lung 'Second Look' system expand the donor pool?
- Can software make hospital pharmacists faster and safer?
- Beyond TB: could a deeper diagnostic look uncover hidden lung diseases?
- Cutting radiation in CT scans: a new test of Ultra-Low-Dose imaging